multiple myeloma
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
BostonGene, Mount Sinai Partner on Multiple Myeloma Precision Oncology Study
The study will use BostonGene's assays, including whole-exome and whole-transcriptome sequencing, to inform patients' clinical care and advance drug development.
First Patient Dosed in Phase I Trial of Cartesian Therapeutics' Anti-BCMA mRNA CAR T-Cell Therapy
The trial will examine the safety and tolerability of Descartes-15 in patients with relapsed or refractory multiple myeloma.
BostonGene, Sylvester Comprehensive Cancer Center Partner on Hematologic Cancer Molecular Subtyping
Researchers will compare traditional tumor profiling methods such as FISH and cytogenetics to BostonGene's AI-powered molecular and immune profiling platform.
Predicta Biosciences Raises $5.2M in Seed Round
The funding will be used to expand the company's team and build a CLIA laboratory and workflow for sequencing and bioinformatics.